Longitudinal analyses of immune responses to Plasmodium falciparum derived peptides corresponding to novel blood stage antigens in coastal Kenya (Q46583308)

From Wikidata

Jump to navigation Jump to search

scientific article published on 26 February 2008

Language	Label	Description	Also known as
English	Longitudinal analyses of immune responses to Plasmodium falciparum derived peptides corresponding to novel blood stage antigens in coastal Kenya	scientific article published on 26 February 2008

Statements

scholarly article

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18342997

Longitudinal analyses of immune responses to Plasmodium falciparum derived peptides corresponding to novel blood stage antigens in coastal Kenya (English)

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18342997

0 references

Plasmodium falciparum

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18342997

7

object named as

Kevin Marsh

1 reference

Europe PubMed Central

23 December 2017

2

object named as

Philip Bejon

1 reference

Europe PubMed Central

23 December 2017

Giampietro Corradin

8

object named as

Giampietro Corradin

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18342997

author name string

George W Agak

1

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18342997

Nimmo Gicheru

4

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18342997

Viviane Villard

5

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18342997

Andrey V Kajava

6

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18342997

language of work or name

0 references

publication date

26 February 2008

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18342997

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18342997

26

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18342997

16

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18342997

1963-1971

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18342997

The past, present and future of childhood malaria mortality in Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

Update on the clinical development of candidate malaria vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

The transcriptome of the intraerythrocytic developmental cycle of Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

A proteomic view of the Plasmodium falciparum life cycle

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

Genome sequence of the human malaria parasite Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

Rapid identification of malaria vaccine candidates based on alpha-helical coiled coil protein motif

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

Boehringer Mannheim award lecture 1995. La conference Boehringer Mannheim 1995. De novo design of alpha-helical proteins: basic research to medical applications

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies to improve vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

Plasmodium falciparum merozoite surface protein 6 displays multiple targets for naturally occurring antibodies that mediate monocyte-dependent parasite killing

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

Kinetics of antibody responses to Plasmodium falciparum-infected erythrocyte variant surface antigens.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

Gamma-globulin and acquired immunity to human malaria.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

The role of antibodies to Plasmodium falciparum-infected-erythrocyte surface antigens in naturally acquired immunity to malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

Anti-merozoite surface protein-1 19-kDa IgG in mother-infant pairs naturally exposed to Plasmodium falciparum: subclass analysis with age, exposure to asexual parasitemia, and protection against malaria. V. The Asembo Bay Cohort Project.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

A novel antibody-dependent cellular cytotoxicity mechanism involved in defense against malaria requires costimulation of monocytes FcgammaRII and FcgammaRIII.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

Mechanisms of defense against P. falciparum asexual blood stages in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

Natural antibody response to Plasmodium falciparum Exp-1, MSP-3 and GLURP long synthetic peptides and association with protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich pro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

The effects of untreated bednets on malaria infection and morbidity on the Kenyan coast

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

Case definitions of clinical malaria under different transmission conditions in Kilifi District, Kenya

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

Plasmodium falciparum infections are associated with agglutinating antibodies to parasite-infected erythrocyte surface antigens among healthy Kenyan children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

Plasmodium post-genomics: an update

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

Pattern of immunoglobulin isotype response to Plasmodium falciparum blood-stage antigens in individuals living in a holoendemic area of Senegal (Dielmo, west Africa).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

Protection against clinical malaria by heterologous immunoglobulin G antibodies against malaria-infected erythrocyte variant surface antigens requires interaction with asymptomatic infections.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

Epidemiological correlation between levels of antibodies promoting merozoite phagocytosis of Plasmodium falciparum and malaria-immune status

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of the role of naturally acquired antibody levels to Plasmodium falciparum merozoite surface protein-1 in protecting Papua New Guinean children from malaria morbidity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.020

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2008.02.020

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18342997

release_i4zh5j2pnvbkzc3cpkaq3dv3aq

1 reference

https://api.fatcat.wiki/v0/release/i4zh5j2pnvbkzc3cpkaq3dv3aq

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18342997

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46583308&oldid=2120551670"